Upgrade to SI Premium - Free Trial

Mizuho Securities Maintains Underperform Rating on Valeant Pharmceuticals (VRX); 'Weaker 2017 EBITDA Outlook'

February 28, 2017 8:54 AM
Mizuho Securities analyst Irina Koffler maintains Underperform rating and $9 price target on Valeant Pharmaceuticals (NYSE: VRX), citing siginificant uncertainty ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Analyst EPS View

Next Articles